Hypoxia-Inducible Factor in Thyroid Carcinoma

被引:40
作者
Burrows, Natalie [1 ]
Babur, Muhammad [1 ]
Resch, Julia [2 ]
Williams, Kaye J. [1 ]
Brabant, Georg [2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Hypoxia & Therapeut Grp, Oxford Rd, Manchester M13 9PT, Lancs, England
[2] Med Klin I, Expt & Clin Endocrinol, D-23538 Lubeck, Germany
基金
英国惠康基金;
关键词
D O I
10.4061/2011/762905
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intratumoural hypoxia (low oxygen tension) is associated with aggressive disease and poor prognosis. Hypoxia-inducible factor-1 is a transcription factor activated by hypoxia that regulates the expression of genes that promote tumour cell survival, progression, metastasis, and resistance to chemo/radiotherapy. In addition to hypoxia, HIF-1 can be activated by growth factor-signalling pathways such as the mitogen-activated protein kinases-(MAPK-) and phosphatidylinositol-3-OH kinases-(PI3K-) signalling cascades. Mutations in these pathways are common in thyroid carcinoma and lead to enhanced HIF-1 expression and activity. Here, we summarise current data that highlights the potential role of both hypoxia and MAPK/PI3K-induced HIF-1 signalling in thyroid carcinoma progression, metastatic characteristics, and the potential role of HIF-1 in thyroid carcinoma response to radiotherapy. Direct or indirect targeting of HIF-1 using an MAPK or PI3K inhibitor in combination with radiotherapy may be a new potential therapeutic target to improve the therapeutic response of thyroid carcinoma to radiotherapy and reduce metastatic burden.
引用
收藏
页数:17
相关论文
共 129 条
[1]   Reasons to reconsider the significance of apoptosis for cancer therapy [J].
Abend, M .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (12) :927-941
[2]  
Aebersold DM, 2001, CANCER RES, V61, P2911
[3]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[4]   Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection [J].
Aprelikova, Olga ;
Wood, Matthew ;
Tackett, Sean ;
Chandramouli, Gadisetti V. R. ;
Barrett, J. Carl .
CANCER RESEARCH, 2006, 66 (11) :5641-5647
[5]   Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer [J].
Astanehe, Arezoo ;
Arenillas, David ;
Wasserman, Wyeth W. ;
Leung, Peter C. K. ;
Dunn, Sandra E. ;
Davies, Barry R. ;
Mills, Gordon B. ;
Auersperg, Nelly .
JOURNAL OF CELL SCIENCE, 2008, 121 (05) :664-674
[6]   VHL and HIF signalling in renal cell carcinogenesis [J].
Baldewijns, Marcella M. ;
van Vlodrop, Iris J. H. ;
Vermeulen, Peter B. ;
Soetekouw, Patricia M. M. B. ;
van Engeland, Manon ;
de Bruine, Adriaan P. .
JOURNAL OF PATHOLOGY, 2010, 221 (02) :125-138
[7]   Hypoxia-inducible factor-1 and oncogenic signalling [J].
Bárdos, JI ;
Athcroft, M .
BIOESSAYS, 2004, 26 (03) :262-269
[8]   Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer [J].
Bass, Michael B. ;
Sherman, Steven I. ;
Schlumberger, Martn J. ;
Davis, Michael T. ;
Kivman, Lisa ;
Khoo, Huan-Mei ;
Notari, Kimberly H. ;
Peach, Matthew ;
Hei, Yong-jiang ;
Patterson, Scott D. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) :5018-5027
[9]   PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR [J].
Bernardi, Rosa ;
Guernah, Ilhem ;
Jin, David ;
Grisendi, Silvia ;
Alimonti, Andrea ;
Teruya-Feldstein, Julie ;
Cordon-Cardo, Carlos ;
Simon, M. Celeste ;
Rafii, Shahin ;
Pandolfi, Pier Paolo .
NATURE, 2006, 442 (7104) :779-785
[10]   Signaling angiogenesis via p42/p44 MAP kinase and hypoxia [J].
Berra, E ;
Milanini, J ;
Richard, DE ;
Le Gall, M ;
Viñals, F ;
Gothié, E ;
Roux, D ;
Pagès, G ;
Pouysségur, J .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1171-1178